Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Keefe

Showing results (201-210 of 255) with videos related to

Pageof 26
Sort By:
Schizophrenia Research|May 27, 2017
Deviation from expected cognitive ability across psychotic disordersW C Hochberger, T Combs, J L Reilly, et al.
Schizophrenia Research|September 28, 2014
Behavioral response inhibition in psychotic disorders: diagnostic specificity, familiality and relation to generalized cognitive deficitLauren E Ethridge, Melanie Soilleux, Paul A Nakonezny, et al.
Biological Psychiatry|September 6, 2005
Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosisRichard S E Keefe, Larry J Seidman, Bruce K Christensen, et al.
Schizophrenia Research|September 21, 2005
Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trialDel D Miller, Joseph P McEvoy, Sonia M Davis, et al.
Schizophrenia Bulletin|June 14, 2015
Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of SchizophreniaDavid Walling, Stephen R Marder, John Kane, et al.
The American Journal of Psychiatry|March 3, 2007
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE studyMarvin S Swartz, Diana O Perkins, T Scott Stroup, et al.
Psychological Medicine|July 12, 2016
Disrupted salience network functional connectivity and white-matter microstructure in persons at risk for psychosis: findings from the LYRIKS studyC Wang, F Ji, Z Hong, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 24, 2026
A phase 2 randomized controlled trial of luvadaxistat in treatment of adults with cognitive impairment associated with schizophrenia: results from the ERUDITE studyNi A Khin, Reuben H Fan, Tingting Ge, et al.
The American Journal of Psychiatry|December 8, 2006
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophreniaRobert A Rosenheck, Douglas L Leslie, Jody Sindelar, et al.
Psychiatry Research|July 31, 2012
Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophreniaLouis S Matza, Glenn A Phillips, Dennis A Revicki, et al.
Pageof 26

Showing results (201-210 of 255) with videos related to

Sort By:
Pageof 26
Schizophrenia Research|May 27, 2017
Deviation from expected cognitive ability across psychotic disordersW C Hochberger, T Combs, J L Reilly, et al.
Schizophrenia Research|September 28, 2014
Behavioral response inhibition in psychotic disorders: diagnostic specificity, familiality and relation to generalized cognitive deficitLauren E Ethridge, Melanie Soilleux, Paul A Nakonezny, et al.
Biological Psychiatry|September 6, 2005
Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosisRichard S E Keefe, Larry J Seidman, Bruce K Christensen, et al.
Schizophrenia Research|September 21, 2005
Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trialDel D Miller, Joseph P McEvoy, Sonia M Davis, et al.
Schizophrenia Bulletin|June 14, 2015
Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of SchizophreniaDavid Walling, Stephen R Marder, John Kane, et al.
The American Journal of Psychiatry|March 3, 2007
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE studyMarvin S Swartz, Diana O Perkins, T Scott Stroup, et al.
Psychological Medicine|July 12, 2016
Disrupted salience network functional connectivity and white-matter microstructure in persons at risk for psychosis: findings from the LYRIKS studyC Wang, F Ji, Z Hong, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 24, 2026
A phase 2 randomized controlled trial of luvadaxistat in treatment of adults with cognitive impairment associated with schizophrenia: results from the ERUDITE studyNi A Khin, Reuben H Fan, Tingting Ge, et al.
The American Journal of Psychiatry|December 8, 2006
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophreniaRobert A Rosenheck, Douglas L Leslie, Jody Sindelar, et al.
Psychiatry Research|July 31, 2012
Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophreniaLouis S Matza, Glenn A Phillips, Dennis A Revicki, et al.
Pageof 26